1039 related articles for article (PubMed ID: 9027592)
1. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
2. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
5. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
6. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
[TBL] [Abstract][Full Text] [Related]
7. Large bowel adenomas: markers of risk and endpoints.
Baron JA
J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
[TBL] [Abstract][Full Text] [Related]
8. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
9. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
11. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
13. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
14. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
Sanner T; Dybing E
Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
[TBL] [Abstract][Full Text] [Related]
15. Biological relevance of adduct detection to the chemoprevention of cancer.
Sharma RA; Farmer PB
Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
[TBL] [Abstract][Full Text] [Related]
16. Progress in clinical chemoprevention.
Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
[TBL] [Abstract][Full Text] [Related]
17. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
Lipkin M
J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
[TBL] [Abstract][Full Text] [Related]
18. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
19. Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer.
Nayfield SG
J Cell Biochem Suppl; 1996; 25():123-30. PubMed ID: 9027608
[TBL] [Abstract][Full Text] [Related]
20. Carcinogen biomarkers for lung or oral cancer chemoprevention trials.
Hecht SS
IARC Sci Publ; 2001; 154():245-55. PubMed ID: 11220664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
